F
Generex Biotechnology Corporation
GNBTQ
OTC PK
D
Sell
5/5/2022Upgraded
Generex Biotechnology Corporation (GNBT) was upgraded to D- from E+ on 5/5/2022 due to an increase in the total return index.
Generex Biotechnology Corporation (GNBT) was upgraded to D- from E+ on 5/5/2022 due to an increase in the total return index.
E
Sell
4/20/2022Downgrade
Generex Biotechnology Corporation (GNBT) was downgraded to E+ from D- on 4/20/2022 due to a decline in the total return index and volatility index.
Generex Biotechnology Corporation (GNBT) was downgraded to E+ from D- on 4/20/2022 due to a decline in the total return index and volatility index.
D
Sell
11/24/2021Downgrade
Generex Biotechnology Corporation (GNBT) was downgraded to D- from D on 11/24/2021 due to a decline in the total return index and volatility index.
Generex Biotechnology Corporation (GNBT) was downgraded to D- from D on 11/24/2021 due to a decline in the total return index and volatility index.
D
Sell
11/9/2021Upgraded
Generex Biotechnology Corporation (GNBT) was upgraded to D from E+ on 11/9/2021 due to an increase in the volatility index and total return index.
Generex Biotechnology Corporation (GNBT) was upgraded to D from E+ on 11/9/2021 due to an increase in the volatility index and total return index.
E
Sell
11/8/2021Downgrade
Generex Biotechnology Corporation (GNBT) was downgraded to E+ from D on 11/8/2021 due to a large decline in the total return index, volatility index and growth index.
Generex Biotechnology Corporation (GNBT) was downgraded to E+ from D on 11/8/2021 due to a large decline in the total return index, volatility index and growth index.
D
Sell
5/1/2020Upgraded
Generex Biotechnology Corporation (GNBT) was upgraded to D from D- on 5/1/2020 due to an increase in the total return index, growth index and volatility index.
Generex Biotechnology Corporation (GNBT) was upgraded to D from D- on 5/1/2020 due to an increase in the total return index, growth index and volatility index.
D
Sell
3/20/2020Downgrade
Generex Biotechnology Corporation (GNBT) was downgraded to D- from D on 3/20/2020 due to a decline in the volatility index, total return index and solvency index. The quick ratio declined from 0.02 to 0.01, and debt to equity increased from -1.04 to -0.82.
Generex Biotechnology Corporation (GNBT) was downgraded to D- from D on 3/20/2020 due to a decline in the volatility index, total return index and solvency index. The quick ratio declined from 0.02 to 0.01, and debt to equity increased from -1.04 to -0.82.
D
Sell
12/17/2019Downgrade
Generex Biotechnology Corporation (GNBT) was downgraded to D from C on 12/17/2019 due to a significant decline in the valuation index, efficiency index and total return index. Net income declined 90.68% from -$4.79M to -$9.13M, and total capital declined 4.26% from $20.13M to $19.28M.
Generex Biotechnology Corporation (GNBT) was downgraded to D from C on 12/17/2019 due to a significant decline in the valuation index, efficiency index and total return index. Net income declined 90.68% from -$4.79M to -$9.13M, and total capital declined 4.26% from $20.13M to $19.28M.
C
Hold
12/28/2018Upgraded
Generex Biotechnology Corporation (GNBT) was upgraded to C from D on 12/28/2018 due to a significant increase in the total return index, efficiency index and growth index. Total revenue increased 171,810% from $1 to $1.72M, total capital increased 114% from -$29.4M to $4.12M, and operating cash flow increased 42.63% from -$621.6 to -$356.6.
Generex Biotechnology Corporation (GNBT) was upgraded to C from D on 12/28/2018 due to a significant increase in the total return index, efficiency index and growth index. Total revenue increased 171,810% from $1 to $1.72M, total capital increased 114% from -$29.4M to $4.12M, and operating cash flow increased 42.63% from -$621.6 to -$356.6.
D
Sell
10/29/2018Downgrade
Generex Biotechnology Corporation (GNBT) was downgraded to D from D+ on 10/29/2018 due to a significant decline in the efficiency index, growth index and solvency index. The quick ratio declined from 0.06 to 0.04, and operating cash flow declined 3.89% from -$598.3 to -$621.6.
Generex Biotechnology Corporation (GNBT) was downgraded to D from D+ on 10/29/2018 due to a significant decline in the efficiency index, growth index and solvency index. The quick ratio declined from 0.06 to 0.04, and operating cash flow declined 3.89% from -$598.3 to -$621.6.
D
Sell
10/15/2018Upgraded
Generex Biotechnology Corporation (GNBT) was upgraded to D+ from D on 10/15/2018 due to an increase in the volatility index and total return index.
Generex Biotechnology Corporation (GNBT) was upgraded to D+ from D on 10/15/2018 due to an increase in the volatility index and total return index.
D
Sell
6/12/2018Downgrade
Generex Biotechnology Corporation (GNBT) was downgraded to D from D+ on 6/12/2018 due to a major decline in the efficiency index and total return index.
Generex Biotechnology Corporation (GNBT) was downgraded to D from D+ on 6/12/2018 due to a major decline in the efficiency index and total return index.
D
Sell
3/16/2018Upgraded
Generex Biotechnology Corporation (GNBT) was upgraded to D+ from D on 3/16/2018 due to an increase in the growth index, total return index and solvency index. Total revenue increased 31,718.18% from $2.2 to $700, EBIT increased 74% from -$636.9 to -$165.6, and operating cash flow increased 52.22% from -$726.2 to -$347.
Generex Biotechnology Corporation (GNBT) was upgraded to D+ from D on 3/16/2018 due to an increase in the growth index, total return index and solvency index. Total revenue increased 31,718.18% from $2.2 to $700, EBIT increased 74% from -$636.9 to -$165.6, and operating cash flow increased 52.22% from -$726.2 to -$347.
D
Sell
2/9/2018Downgrade
Generex Biotechnology Corporation (GNBT) was downgraded to D from D+ on 2/9/2018 due to a decline in the volatility index.
Generex Biotechnology Corporation (GNBT) was downgraded to D from D+ on 2/9/2018 due to a decline in the volatility index.
D
Sell
1/25/2018Upgraded
Generex Biotechnology Corporation (GNBT) was upgraded to D+ from D on 1/25/2018 due to an increase in the volatility index and total return index.
Generex Biotechnology Corporation (GNBT) was upgraded to D+ from D on 1/25/2018 due to an increase in the volatility index and total return index.
D
Sell
12/15/2017Downgrade
Generex Biotechnology Corporation (GNBT) was downgraded to D from D+ on 12/15/2017 due to a noticeable decline in the growth index. Operating cash flow declined 13.08% from -$642.2 to -$726.2.
Generex Biotechnology Corporation (GNBT) was downgraded to D from D+ on 12/15/2017 due to a noticeable decline in the growth index. Operating cash flow declined 13.08% from -$642.2 to -$726.2.
D
Sell
7/31/2017Upgraded
Generex Biotechnology Corporation (GNBT) was upgraded to D+ from D on 7/31/2017 due to an increase in the efficiency index, volatility index and growth index.
Generex Biotechnology Corporation (GNBT) was upgraded to D+ from D on 7/31/2017 due to an increase in the efficiency index, volatility index and growth index.
D
Sell
6/6/2017Downgrade
Generex Biotechnology Corporation (GNBT) was downgraded to D from D+ on 6/6/2017 due to a major decline in the total return index and volatility index.
Generex Biotechnology Corporation (GNBT) was downgraded to D from D+ on 6/6/2017 due to a major decline in the total return index and volatility index.
D
Sell
3/23/2017Downgrade
Generex Biotechnology Corporation (GNBTD) was downgraded to D+ from C- on 3/23/2017 due to a noticeable decline in the growth index, total return index and volatility index. Earnings per share declined from $0.6166 to -$17.16, operating cash flow declined 2,002.88% from -$10.4 to -$218.7, and EBIT declined 109.82% from -$102.8 to -$215.7.
Generex Biotechnology Corporation (GNBTD) was downgraded to D+ from C- on 3/23/2017 due to a noticeable decline in the growth index, total return index and volatility index. Earnings per share declined from $0.6166 to -$17.16, operating cash flow declined 2,002.88% from -$10.4 to -$218.7, and EBIT declined 109.82% from -$102.8 to -$215.7.
C
Hold
3/13/2017Upgraded
Generex Biotechnology Corporation (GNBT) was upgraded to C- from D+ on 3/13/2017 due to a noticeable increase in the total return index.
Generex Biotechnology Corporation (GNBT) was upgraded to C- from D+ on 3/13/2017 due to a noticeable increase in the total return index.
D
Sell
2/9/2017Downgrade
Generex Biotechnology Corporation (GNBT) was downgraded to D+ from C- on 2/9/2017 due to a decline in the volatility index.
Generex Biotechnology Corporation (GNBT) was downgraded to D+ from C- on 2/9/2017 due to a decline in the volatility index.
C
Hold
1/25/2017Upgraded
Generex Biotechnology Corporation (GNBT) was upgraded to C- from D+ on 1/25/2017 due to a large increase in the volatility index and total return index.
Generex Biotechnology Corporation (GNBT) was upgraded to C- from D+ on 1/25/2017 due to a large increase in the volatility index and total return index.
D
Sell
1/19/2017Upgraded
Generex Biotechnology Corporation (GNBT) was upgraded to D+ from D on 1/19/2017 due to a noticeable increase in the growth index and volatility index. Earnings per share increased from -$0.0026 to $0.0006, operating cash flow increased 86.58% from -$77.5 to -$10.4, and EBIT increased 63.7% from -$283.2 to -$102.8.
Generex Biotechnology Corporation (GNBT) was upgraded to D+ from D on 1/19/2017 due to a noticeable increase in the growth index and volatility index. Earnings per share increased from -$0.0026 to $0.0006, operating cash flow increased 86.58% from -$77.5 to -$10.4, and EBIT increased 63.7% from -$283.2 to -$102.8.
D
Sell
1/13/2017Downgrade
Generex Biotechnology Corporation (GNBT) was downgraded to D from D+ on 1/13/2017 due to a decline in the volatility index and solvency index. The quick ratio declined from 0.01 to 0.
Generex Biotechnology Corporation (GNBT) was downgraded to D from D+ on 1/13/2017 due to a decline in the volatility index and solvency index. The quick ratio declined from 0.01 to 0.
D
Sell
3/11/2016Downgrade
Generex Biotechnology Corp. (GNBT) was downgraded to D+ from C- on 3/11/2016 due to a substantial decline in the volatility index and total return index.
Generex Biotechnology Corp. (GNBT) was downgraded to D+ from C- on 3/11/2016 due to a substantial decline in the volatility index and total return index.
C
Hold
1/15/2016Downgrade
Generex Biotechnology Corp. (GNBT) was downgraded to C- from C on 1/15/2016 due to a significant decline in the valuation index, growth index and solvency index. The quick ratio declined from 0.09 to 0.01.
Generex Biotechnology Corp. (GNBT) was downgraded to C- from C on 1/15/2016 due to a significant decline in the valuation index, growth index and solvency index. The quick ratio declined from 0.09 to 0.01.
C
Hold
8/7/2015Upgraded
Generex Biotechnology Corp. (GNBT) was upgraded to C from C- on 8/7/2015 due to a significant increase in the valuation index.
Generex Biotechnology Corp. (GNBT) was upgraded to C from C- on 8/7/2015 due to a significant increase in the valuation index.
C
Hold
6/5/2015Upgraded
Generex Biotechnology Corp. (GNBT) was upgraded to C- from D+ on 6/5/2015 due to an increase in the efficiency index. Net income increased 172.75% from -$511.9 to -$1.4M, and total capital increased 20.73% from -$6.4M to -$7.72M.
Generex Biotechnology Corp. (GNBT) was upgraded to C- from D+ on 6/5/2015 due to an increase in the efficiency index. Net income increased 172.75% from -$511.9 to -$1.4M, and total capital increased 20.73% from -$6.4M to -$7.72M.
D
Sell
3/6/2015Downgrade
Generex Biotechnology Corp. (GNBT) was downgraded to D+ from C- on 3/6/2015 due to a decline in the efficiency index, valuation index and total return index. Net income declined 1,132.06% from $49.6 to -$511.9.
Generex Biotechnology Corp. (GNBT) was downgraded to D+ from C- on 3/6/2015 due to a decline in the efficiency index, valuation index and total return index. Net income declined 1,132.06% from $49.6 to -$511.9.
C
Hold
10/10/2014Downgrade
Generex Biotechnology Corp. (GNBT) was downgraded to C- from C on 10/10/2014 due to a large decline in the efficiency index and valuation index. Total capital declined 28.05% from -$8.46M to -$6.09M.
Generex Biotechnology Corp. (GNBT) was downgraded to C- from C on 10/10/2014 due to a large decline in the efficiency index and valuation index. Total capital declined 28.05% from -$8.46M to -$6.09M.
